迷路内原发肿瘤的临床特征与手术治疗
回顾性分析41例迷路内原发肿瘤患者,最常见症状为听力下降(95.1%),平均纯音听阈(97.1±29.0)dBHL,多为重度以上感音神经性听力损失。19例接受手术,术后病理多为神经鞘瘤,随访仅1例复发。治疗可选择影像随访或手术,术式与听力重建需综合多因素决定。
要点
- 听力下降是最常见症状,多为重度以上感音神经性听力损失。
- 颞骨薄层MRI强化扫描是最有价值的影像检查手段。
- 治疗可影像随访或手术,术式与听力重建需个体化综合评估。
核心结论
- 迷路内原发肿瘤主要表现为听力下降,大多为重度以上感音神经性听力损失。
- 治疗策略可选择影像随访或外科手术,术式及听力重建需综合肿瘤大小、侵犯部位、健侧听力及患者需求决定。
研究设计与样本
- 回顾性分析2011年8月至2024年12月山东省第二人民医院诊治的41例迷路内原发肿瘤患者临床资料。
- 男16例、女25例,年龄(49.6±11.4)岁,左侧20例、右侧21例,均经高分辨率MRI诊断。
- 19例接受手术治疗并经术后病理确诊,手术患者进行影像随访。
主要发现
- 最常见症状为听力下降(95.1%,39/41),其次为耳鸣(85.4%,35/41)、眩晕/头晕(39.0%,16/41)、耳闷(36.6%,15/41)。
- WHO听力损失分级:轻度1例、中度1例、中重度5例、重度5例、极重度5例、完全听力损失24例。
- AAO-HNS听力分级:A级1例、B级1例、C级2例、D级37例。
- 肿瘤侵犯部位分类:耳蜗型24例、前庭耳蜗型8例、跨耳囊型5例(其中2例侵犯桥小脑角)、前庭型3例、跨蜗轴型1例。
关键数值与推荐
- 22例选择随访观察,19例选择手术治疗。
- 5例跨耳囊型患者中4例采取分期手术,5例同期植入人工耳蜗,3例于耳内镜下经耳道鼓岬入路切除肿瘤。
- 术后病理18例为神经鞘瘤,1例为神经纤维瘤。
- 手术患者随访6个月至10年,1例术后3年发现残余耳蜗内复发,再次手术后痊愈,其余未见复发。
临床怎么用
- 对疑似迷路内肿瘤患者应行颞骨薄层MRI强化扫描以明确诊断。
- 根据肿瘤大小、侵犯部位、健侧听力及患者需求,个体化选择影像随访或手术。
- 手术径路选择及是否同期听力重建需综合评估,跨耳囊型可考虑分期手术。
局限性
- 本研究为单中心回顾性分析,样本量41例,随访时间不等。
- 仅19例手术患者有病理确诊,随访观察患者未行病理诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the clinical characteristics of primary intralabyrinthine tumors and to explore effective diagnostic and therapeutic strategies. Methods: A retrospective analysis was conducted on the clinical data of 41 patients with primary intralabyrinthine tumors diagnosed and treated at Shandong Second Provincial General Hospital (Shandong Provincial ENT Hospital) from August 2011 to December 2024. There were 16 males and 25 females, with a mean age of (49.6±11.4) years (mean±standard deviation); 20 cases occurred on the left side and 21 on the right side. All cases were diagnosed by high-resolution magnetic resonance imaging (HR-MRI), and 19 of them underwent surgical treatment, with the diagnosis confirmed by postoperative pathology. Imaging follow-up was performed for the surgical patients, and their clinical symptoms, imaging features, intervention methods, and therapeutic outcomes were summarized and analyzed. Results: Among the 41 patients, the most common symptom was hearing loss (39/41, 95.1%), followed by tinnitus (35/41, 85.4%), vertigo/dizziness (16/41, 39.0%), and ear fullness (15/41, 36.6%). The pure tone average (PTA) at 500, 1 000, 2 000, and 4 000 Hz was (97.1±29.0) dBHL. According to the WHO hearing loss classification, there were 1 case of mild hearing loss, 1 case of moderate hearing loss, 5 cases of moderately severe hearing loss, 5 cases of severe hearing loss, 5 cases of profound hearing loss, and 24 cases of total hearing loss. According to the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) hearing classification, there were 1 case of Class A, 1 case of Class B, 2 cases of Class C, and 37 cases of Class D. Classification by tumor invasion site showed 24 cases of intracochlear type, 8 cases of vestibulocochlear type, 5 cases of transotic type (2 of which invaded the cerebellopontine angle), 3 cases of intravestibular type, and 1 case of transmodiolar type. For treatment modalities, 22 patients opted for follow-up observation, and 19 patients underwent surgical treatment (4 out of 5 transotic patients received staged surgery; 5 patients underwent simultaneous cochlear implantation; and 3 patients underwent tumor resection via the transcanal promontory approach under otoendoscopy). Postoperative pathological results revealed that 18 cases were schwannomas, and 1 case was neurofibroma. The follow-up duration for surgical patients ranged from 6 months to 10 years. Only 1 patient had residual tumor recurrence in the cochlea 3 years after surgery, and achieved complete recovery after reoperation; no recurrence was observed in the other surgical patients. Conclusions: Intralabyrinthine tumors are mainly characterized by hearing loss, most of which are sensorineural hearing loss of severe degree or above. Enhanced thin-slice MRI of the temporal bone is the most valuable imaging examination method. The treatment strategy can be either imaging follow-up or surgical intervention. The selection of surgical approach and whether to perform hearing reconstruction should comprehensively consider factors such as tumor size, invasion site, hearing status of the contralateral ear, and patient needs. 目的: 分析迷路内原发肿瘤的临床特征,探索有效的诊断、治疗策略。 方法: 回顾分析2011年8月至2024年12月间山东省第二人民医院(山东省耳鼻喉医院)诊治的41例迷路内原发肿瘤患者的临床资料,其中男性16例、女性25例,年龄(49.6±11.4)岁(均数±标准差),左侧20例、右侧21例。所有病例均经高分辨率MRI诊断,其中19例接受手术治疗,术后病理确诊。手术患者进行影像随访,总结分析患者的临床症状、影像特点、干预方式及疗效结果。 结果: 41例迷路内原发肿瘤患者最常见的症状为听力下降(95.1%,39/41),其次为耳鸣(85.4%,35/41)、眩晕/头晕(39.0%,16/41)以及耳闷(36.6%,15/41)。平均纯音听阈(500、1 000、2 000、4 000 Hz)为(97.1±29.0)dBHL;根据世界卫生组织(WHO)听力损失分级标准:轻度听力损失1例、中度听力损失1例、中重度听力损失5例、重度听力损失5例、极重度听力损失5例、完全听力损失24例;根据美国耳鼻咽喉头颈外科学会(AAO-HNS)听力分级标准:A级1例,B级1例,C级2例,D级37例。根据肿瘤侵犯部位分类:耳蜗型24例、前庭耳蜗型8例、跨耳囊型5例(2例侵犯桥小脑角)、前庭型3例、跨蜗轴型1例。22例患者选择随访观察,19例患者选择了手术治疗(5例跨耳囊型患者中4例采取分期手术,5例患者同期植入人工耳蜗,另有3例于耳内镜下经耳道鼓岬入路切除肿瘤)。术后病理除1例为神经纤维瘤外,其余均为神经鞘瘤。手术患者随访6个月~10年,1例术后3年发现残余耳蜗内复发,再次手术后痊愈,余手术患者未见复发。 结论: 迷路内肿瘤主要表现为听力下降,且大多为重度以上感音神经性听力损失。颞骨薄层MRI强化扫描是最有价值的影像检查手段。治疗策略可选择影像随访或外科手术,手术径路的选择以及是否进行听力重建、需综合考虑肿瘤的大小、侵犯部位、健侧听力以及患者需求等。.
引用
- Sun PC, Jiang Z, Xu L, et al. [Clinical characteristics and surgical management of primary intralabyrinthine tumor]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2025. PMID: 41429488. doi:10.3760/cma.j.cn115330-20250311-00139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。